scholarly journals A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Stephan A Ohnmacht ◽  
Chiara Marchetti ◽  
Mekala Gunaratnam ◽  
Rachael J Besser ◽  
Shozeb M Haider ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
In Vivo Model ◽  
Anti Tumour Activity ◽  
G Quadruplex ◽  
Tumour Activity

Effect of ARK5 on the anti-tumour activity of OSI-027 via regulation of epithelial-mesenchymal transition in pancreatic cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15758-e15758
Author(s):  
Xiao Zhi ◽  
Tingbo Liang
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Cells ◽  
Epithelial Mesenchymal Transition ◽  
Mesenchymal Transition ◽  
Pancreatic Cancer Cells ◽  
Anti Tumour Activity ◽  
Tumour Activity ◽  
Anti Tumour Effect

e15758 Background: Pancreatic cancer (PC) is one of the most common lethal malignancies,OSI-027, a selective inhibitor of mTOR, has anti-tumour activity in PC and is currently in phase II clinical trials. According to the results of our previous study, OSI-027 sensitivity varies across pancreatic cancer cell lines; however, the underlying mechanisms are unclear. Methods: In this study,We sought to investigate the regulatory mechanisms underlying OSI-027 resistance in PC under both in vitro and in vivo conditions. Results: We demonstrated that in PC, sensitivity to OSI-027 was negatively correlated with ARK5 expression, and ARK5 knockdown could enhance OSI-027 sensitivity. Further, the mechanistic experiments showed that ARK5 inhibition could reverse EMT induced by OSI-027. Suppression of EMT by Twist siRNA could sensitize pancreatic cancer cells to OSI-027, but the combination of Twist siRNA and ARK5 siRNA did not enhance the anti-tumour effect of OSI-027. Moreover, under hypoxia-induced EMT, the cancer cells were less sensitive to OSI-027, but ARK5 siRNA could block the EMT process. The in vivo experiments showed that the combination of ARK5 and Twist siRNAs could enhance the anti-tumour effect of OSI-027 and restrain OSI-027-induced EMT. Conclusions: The results indicate that ARK5 plays a role in the resistance of pancreatic cancer cells to OSI-027 by regulating EMT and lay the groundwork for future clinical studies.

scholarly journals Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma

Leukemia ◽  
2021 ◽  
Author(s):  
Charlotte Elizabeth Graham ◽  
Agnieszka Jozwik ◽  
Ruby Quartey-Papafio ◽  
Nikolaos Ioannou ◽  
Ana M. Metelo ◽  
...  
Keyword(s):  
T Cells ◽  
Healthy Donor ◽  
In Vivo Model ◽  
High Grade ◽  
Car T Cells ◽  
Anti Tumour Activity ◽  
Car T ◽  
Tumour Activity

Porphyrins to restrict progression of pancreatic cancer by stabilizing KRAS G-quadruplex: In silico, in vitro and in vivo validation of anticancer strategy

2018 ◽  
Vol 125 ◽  
pp. 39-53 ◽  
Author(s):  
Rudradip Pattanayak ◽  
Atish Barua ◽  
Amlan Das ◽  
Tanima Chatterjee ◽  
Adrija Pathak ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
In Silico ◽  
G Quadruplex ◽  
In Vivo Validation

An orthotopic in vivo model of human pancreatic cancer

Surgery ◽  
1999 ◽  
Vol 126 (3) ◽  
pp. 562-567 ◽  
Author(s):  
Roderich E. Schwarz ◽  
Todd M. McCarty ◽  
Elizabeth A. Peralta ◽  
Don J. Diamond ◽  
Joshua D.I. Ellenhorn
Keyword(s):  
Pancreatic Cancer ◽  
Human Pancreatic Cancer ◽  
In Vivo Model

scholarly journals Ex vivo cytotoxicity and in vivo anti-tumour activity of a novel highly selective STAT3 inhibitor YHO-1701 for ovarian and endometrial cancer

2019 ◽  
Vol 30 ◽  
pp. v424
Author(s):  
K. Hasegawa ◽  
K. Taniguchi ◽  
S. Sato ◽  
A. Yoshinaga ◽  
M. Tsugane ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Ex Vivo ◽  
Anti Tumour Activity ◽  
Tumour Activity

In vivo Anti-Tumour Activity of Ethyl Heptyloxyacetate against Ehrlich Ascites Cells

Nature ◽  
1963 ◽  
Vol 198 (4878) ◽  
pp. 384-385 ◽  
Author(s):  
GORDON F. TOWNSEND ◽  
WILLIAM H. BROWN ◽  
ETHEL E. FELAUER
Keyword(s):  
Anti Tumour Activity ◽  
Ehrlich Ascites ◽  
Ehrlich Ascites Cells ◽  
Tumour Activity

In vivo andin vitro anti-tumour activity of dimaprit

1985 ◽  
Vol 16 (3-4) ◽  
pp. 284-286 ◽  
Author(s):  
Antoinette Fray ◽  
Claude Burtin ◽  
Pierre Scheinmann ◽  
Geneviève Lespinats ◽  
Paulette Canu
Keyword(s):  
Anti Tumour Activity ◽  
Tumour Activity

scholarly journals VP-128, a novel oestradiol-platinum(II) hybrid with selective anti-tumour activity towards hormone-dependent breast cancer cells in vivo

2009 ◽  
Vol 16 (4) ◽  
pp. 1185-1195 ◽  
Author(s):  
Céline Van Themsche ◽  
Sophie Parent ◽  
Valérie Leblanc ◽  
Caroline Descôteaux ◽  
Anne-Marie Simard ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Nuclear Accumulation ◽  
Dependent Manner ◽  
Anti Tumour Activity ◽  
Tumour Activity ◽  
Mcf 7

We have previously reported the synthesis of VP-128, a new 17β-oestradiol (E2)-linked platinum(II) hybrid with high affinity for oestrogen receptor α (ERα). In the present study, we have investigated the anti-tumour activity of VP-128 towards breast cancer cells in vitro and in vivo. We used human ERα-positive (MCF-7) and -negative (MDA-MB-468) cells as a model for treatment with increasing doses of VP-128, cisplatin or E2 in vitro and for xenograft experiments in nude mice in vivo. Compared with cisplatin, VP-128 showed markedly improved in vitro and in vivo anti-tumour activity towards ERα-positive MCF-7 breast cancer cells, without increased systemic toxicity. In these caspase-3-deficient cells, treatment with VP-128 overcame weak cellular sensitivity to cisplatin in vitro and in vivo. In these cells, only the hybrid induced apoptosis in an ERα-dependent manner, inactivated both X-linked inhibitor of apoptosis protein and Akt, and induced selective nuclear accumulation of ERα and the expression of ER-regulated genes c-myc and tff1, which was blocked by ERα-specific antagonist ICI 282 780. In the case of ERα-negative MDA-MB-468 cells, VP-128, but not cisplatin, induced nuclear accumulation of apoptosis-inducing factor and inhibited c-myc expression. However, VP-128 did not show enhanced in vivo anti-tumour activity compared with cisplatin. These results reveal two different modes of action for VP-128 in ERα-positive and -negative breast cancer cells, and highlight the promising therapeutic value of this unique E2-platinum hybrid for selective targeting of hormone-dependent cancers.

scholarly journals Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate

1999 ◽  
Vol 80 (8) ◽  
pp. 1252-1258 ◽  
Author(s):  
L Qiu ◽  
M J Kelso ◽  
C Hansen ◽  
M L West ◽  
D P Fairlie ◽  
...  
Keyword(s):  
Anti Tumour Activity ◽  
Differentiating Agents ◽  
Tumour Activity
Sign in / Sign up

Export Citation Format

Share Document